Graz, Austria

Robert Wronski

This inventor holds 1 USPTO granted patent. Top assignee: Jsw-Research Forschungslabor Gmbh. Active years: 2011.


Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2011

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Robert Wronski

Introduction

Robert Wronski is an accomplished inventor based in Graz, Austria. He has made significant contributions to the field of neurodegenerative disease treatment through his innovative research and development of pharmaceutical agents. His work focuses on the use of peptidomimetic agents derived from dextrorotatory amino acids.

Latest Patents

Robert Wronski holds a patent for "Peptidomimetic agents from dextrorotatory amino acids as well as pharmaceutical agents that contain the latter for treatment of neurodegenerative diseases." This patent includes a peptidomimetic agent featuring vGek with Dval-gly-Dglu-Dlys as a central D-amino acid sequence. The pharmaceutical agents developed under this patent are aimed at treating various neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's Chorea disease.

Career Highlights

Throughout his career, Robert has been associated with Jsw-Research Forschungslabor GmbH, where he has been instrumental in advancing research in neurodegenerative diseases. His innovative approach and dedication to improving treatment options have positioned him as a notable figure in the field.

Collaborations

Robert Wronski has collaborated with esteemed colleagues such as Birgit Hutter-Paier and Manfred Windisch. These partnerships have further enhanced the research and development efforts at Jsw-Research.

Conclusion

Robert Wronski's contributions to the field of neurodegenerative disease treatment through his innovative patents and collaborations highlight his commitment to advancing medical science. His work continues to pave the way for new therapeutic options for patients suffering from these challenging conditions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…